MCLA-145
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MCLA-145 |
| Trade Name | |
| Synonyms | MCLA145|MCLA 145|anti-PD-L1/4-1BB bispecific antibody |
| Drug Descriptions |
MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 TNFRSF9 Antibody 36 |
| CAS Registry Number | NA |
| NCIT ID | C160772 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| MCLA-145 | MCLA-145 | 0 | 1 |
| MCLA-145 + Pembrolizumab | MCLA-145 Pembrolizumab | 0 | 0 |
CKB BOOST